Targeting the translation machinery in cancer (original) (raw)

• Sonenberg, N. & Hinnebusch, A. G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136, 731–745 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Buttgereit, F. & Brand, M. D. A hierarchy of ATP-consuming processes in mammalian cells. Biochem. J. 312, 163–167 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Rolfe, D. F. & Brown, G. C. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol. Rev. 77, 731–758 (1997).
  Article CAS PubMed Google Scholar
• Mathews, M., Sonenberg, N. & Hershey, J. W. B. in Translational Control in Biology and Medicine 3rd edn (eds Mathews, M. et al.) Ch. 1 (Cold Spring Harbor Laboratory Press, 2007).
  Google Scholar
• Hershey, J. W. B., Sonenberg, N. & Mathews, M. in Protein Synthesis and Translational Control (eds Hershey, J. W. B. et al.) (Cold Spring Harbor Laboratory Press, 2012)
  Google Scholar
• Johnson, L. F. et al. Changes in RNA in relation to growth of the fibroblast. IV. Alterations in the production and processing of mRNA and rRNA in resting and growing cells. J. Cell Biol. 71, 933–938 (1976).
  Article CAS PubMed Google Scholar
• Colina, R. et al. Translational control of the innate immune response through IRF-7. Nature 452, 323–328 (2008).
  Article CAS PubMed Google Scholar
• Larsson, O. et al. Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res. 67, 6814–6824 (2007).
  Article CAS PubMed Google Scholar
• Larsson, O. et al. Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure. Nucleic Acids Res. 34, 4375–4386 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Polunovsky, V. A. et al. Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol. Cell. Biol. 16, 6573–6581 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Kevil, C. G. et al. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int. J. Cancer 65, 785–790 (1996).
  Article CAS PubMed Google Scholar
• Walsh, D., Mathews, M. B. & Mohr, I. Tinkering with translation: protein synthesis in virus-infected cells. Cold Spring Harb. Perspect. Biol. 5, a012351 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Topisirovic, I. & Sonenberg, N. mRNA translation and energy metabolism in cancer: the pole of the MAPK and mTORC1 pathways. Cold Spring Harb. Symp. Quant. Biol. 76, 355–367 (2011).
  Article CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
  Article CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  Article CAS PubMed Google Scholar
• Ivanov, P. & Anderson, P. Post-transcriptional regulatory networks in immunity. Immunol. Rev. 253, 253–272 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Cho, P. F. et al. Cap-dependent translational inhibition establishes two opposing morphogen gradients in Drosophila embryos. Curr. Biol. 16, 2035–2041 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Kang, H. & Schuman, E. M. A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity. Science 273, 1402–1406 (1996).
  Article CAS PubMed Google Scholar
• Schwanhausser, B. et al. Global quantification of mammalian gene expression control. Nature 473, 337–342 (2011).
  Article CAS PubMed Google Scholar
• Ghazalpour, A. et al. Comparative analysis of proteome and transcriptome variation in mouse. PLoS Genet. 7, e1001393 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Vogel, C. & Marcotte, E. M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nature Rev. Genet. 13, 227–232 (2012).
  Article CAS PubMed Google Scholar
• Kristensen, A. R., Gsponer J. & Foster, L. J. Protein synthesis rate is the predominant regulator of protein expression during differentiation. Mol. Syst. Biol. 9, 689 (2013).
  Article PubMed PubMed Central Google Scholar
• Pianese, G. Beitrag zur histologie und aetiologie der carcinoma histologische und experimentelle. Beitr. Pathol. Anat. Allg. Pathol. 142, 1–193 (in German) (1896). First evidence that dysregulated translation has a major role in cancer by demonstrating that cancer cells have hypertrophic and irregularly shaped nucleoli.
  Google Scholar
• Loreni, F., Mancino, M. & Biffo, S. Translation factors and ribosomal proteins control tumor onset and progression: how? Oncogene 33, 2145–2156 (2014).
  Article CAS PubMed Google Scholar
• Teng, T. G. Thomas & Mercer, C. A. Growth control and ribosomopathies. Curr. Opin. Genet. Dev. 23, 63–71 (2013).
  Article CAS PubMed Google Scholar
• Ruggero, D. Translational control in cancer etiology. Cold Spring Harb. Perspect. Biol. 5, a012336 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Ganapathi, K. A. & Shimamura, A. Ribosomal dysfunction and inherited marrow failure. Br. J. Haematol. 141, 376–387 (2008).
  Article CAS PubMed Google Scholar
• Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Silvera, D. S., Formenti, C. & Schneider, R. J. Translational control in cancer. Nature Rev. Cancer 10, 254–266 (2010).
  Article CAS Google Scholar
• Rosenwald, I. B. et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J. Biol. Chem. 270, 21176–21180 (1995).
  Article CAS PubMed Google Scholar
• Fagan, R. J. et al. Translational control of ornithine aminotransferase. Modulation by initiation factor eIF-4E. J. Biol. Chem. 266, 16518–16523 (1991).
  CAS PubMed Google Scholar
• De Benedetti, A. et al. CHO cells transformed by the translation factor elF-4E display increased c-Myc expression, but require overexpression of Max for tumorigenicity. Mol. Cell. Diff. 2, 347–371 (1994).
  CAS Google Scholar
• Cunningham, J. T. et al. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell 157, 1088–1103 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• De Benedetti, A. & Graff, J. R. eIF-4E expression and its role in malignancies and metastases. Oncogene 23, 3189–3199 (2004).
  Article CAS PubMed Google Scholar
• Koromilas, A. E., Lazaris-Karatzas, A. & Sonenberg, N. mRNAs containing extensive secondary structure in their 5′ non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E. EMBO J. 11, 4153–4158 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Svitkin, Y. V. et al. The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5′ secondary structure. RNA 7, 382–394 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Pause, A. et al. Dominant negative mutants of mammalian translation initiation factor eIF-4A define a critical role for eIF-4F in cap-dependent and cap-independent initiation of translation. EMBO J. 13, 1205–1215 (1994).
  Article CAS PubMed PubMed Central Google Scholar
• Hiremath, L. S., Webb, N. R. & Rhoads, R. E. Immunological detection of the messenger RNA cap-binding protein. J. Biol. Chem. 260, 7843–7849 (1985).
  CAS PubMed Google Scholar
• Duncan, R., Milburn, S. C. & Hershey, J. W. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J. Biol. Chem. 262, 380–388 (1987).
  CAS PubMed Google Scholar
• Feoktistova, K. et al. Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity. Proc. Natl Acad. Sci. USA 110, 13339–13344 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Ramirez-Valle, F. et al. eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J. Cell Biol. 181, 293–307 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Wolfe, A. L. et al. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. Nature 513, 65–70 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274–293 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Hall, M. N. Talks about TORCs: recent advances in target of rapamycin signalling. On mTOR nomenclature. Biochem. Soc. Trans. 41, 887–888 (2013).
  Article CAS PubMed Google Scholar
• Caron, E. et al. A comprehensive map of the mTOR signaling network. Mol. Syst. Biol. 6, 453 (2010).
  Article PubMed PubMed Central Google Scholar
• Oh, W. J. & Jacinto, E. mTOR complex 2 signaling and functions. Cell Cycle 10, 2305–2316 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Roux, P. P. & Topisirovic, I. Regulation of mRNA translation by signaling pathways. Cold Spring Harb. Perspect. Biol. 4, a012252 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Pause, A. et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 371, 762–767 (1994). This is the first study to show that 4E-BPs act as translational repressors by impairing the formation of the eIF4F complex.
  Article CAS PubMed Google Scholar
• Beretta, L. et al. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J. 15, 658–664 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Brunn, G. J. et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277, 99–101 (1997).
  Article CAS PubMed Google Scholar
• Gingras, A. C. et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13, 1422–1437 (1999). This study unravels the hierarchical mechanism of 4E-BP phosphorylation by mTOR, which induces dissociation of 4E-BPs from eIF4E, thereby facilitating eIF4E–eIF4G binding and assembly of the eIF4F complex.
  Article CAS PubMed PubMed Central Google Scholar
• Gingras, A. C. et al. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 12, 502–513 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• von Manteuffel, S. R. et al. 4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. Proc. Natl Acad. Sci. USA 93, 4076–4080 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Burnett, P. E. et al. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl Acad. Sci. USA 95, 1432–1437 (1998). References 53 and 54 are two of the first studies to show that phosphorylation of 4E-BPs is regulated by mTOR kinase (also known as FRAP and RAFT1).
  Article CAS PubMed PubMed Central Google Scholar
• Zheng, J. et al. Phosphorylated Mnk1 and eIF4E are associated with lymph node metastasis and poor prognosis of nasopharyngeal carcinoma. PLoS ONE 9, e89220 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Hara, K. et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J. Biol. Chem. 272, 26457–26463 (1997).
  Article CAS PubMed Google Scholar
• Brown, E. J. et al. Control of p70 S6 kinase by kinase activity of FRAP in vivo. Nature 377, 441–446 (1995).
  Article CAS PubMed Google Scholar
• Hara, K. et al. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem. 273, 14484–14494 (1998).
  Article CAS PubMed Google Scholar
• Banerjee, P. et al. Molecular structure of a major insulin/mitogen-activated 70-kDa S6 protein kinase. Proc. Natl Acad. Sci. USA 87, 8550–8554 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Raught, B. et al. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J. 23, 1761–1769 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Dorrello, N. V. et al. S6K1- and βTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314, 467–471 (2006).
  Article CAS PubMed Google Scholar
• Yang, H. S. et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol. Cell. Biol. 23, 26–37 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Raught, B. et al. Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J. 19, 434–444 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, X. et al. Regulation of elongation factor 2 kinase by p90RSK1 and p70 S6 kinase. EMBO J. 20, 4370–4379 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Mayer, C. et al. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev. 18, 423–434 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Michels, A. A. et al. mTORC1 directly phosphorylates and regulates human MAF1. Mol. Cell. Biol. 30, 3749–3757 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Meyuhas, O. & Dreazen, A. Ribosomal protein S6 kinase from TOP mRNAs to cell size. Prog. Mol. Biol. Transl. Sci. 90, 109–153 (2009).
  Article CAS PubMed Google Scholar
• Ingolia, N. T. et al. Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science 324, 218–223 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Thoreen, C. C. et al. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109–113 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Hsieh, A. C. et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485, 55–61 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Larsson, O., Tian, B. & Sonenberg, N. Toward a genome-wide landscape of translational control. Cold Spring Harb. Perspect. Biol. 5, a012302 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Larsson, O. et al. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc. Natl Acad. Sci. USA 109, 8977–8982 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Morita, M. et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 18, 698–711 (2013).
  Article CAS PubMed Google Scholar
• Miloslavski, R. et al. Oxygen sufficiency controls TOP mRNA translation via the TSC–Rheb–mTOR pathway in a 4E-BP-independent manner. J. Mol. Cell Biol. 6, 255–266 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Tcherkezian, J. et al. Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5′TOP mRNA translation. Genes Dev. 28, 357–371 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Hsu, P. P. et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317–1322 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Aoki, K. et al. LARP1 specifically recognizes the 3′ terminus of poly(A) mRNA. FEBS Lett. 587, 2173–2178 (2013).
  Article CAS PubMed Google Scholar
• Waskiewicz, A. J. et al. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol. Cell. Biol. 19, 1871–1880 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Cargnello, M. & Roux, P. P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 75, 50–83 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Buxade, M., Parra-Palau, J. L. & Proud, C. G. The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front. Biosci. 13, 5359–5373 (2008).
  Article CAS PubMed Google Scholar
• Waskiewicz, A. J. et al. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 16, 1909–1920 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Fukunaga, R. & Hunter, T. MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J. 16, 1921–1933 (1997). References 81 and 82 establish a role for MNKs in phosphorylating eIF4E downstream of MAPKs.
  Article CAS PubMed PubMed Central Google Scholar
• Scheper, G. C. et al. The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells. Mol. Cell. Biol. 21, 743–754 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Pyronnet, S. et al. Human eukaryotic translation initiation factor 4G (eIF4G) recruits Mnk1 to phosphorylate eIF4E. EMBO J. 18, 270–279 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Walsh, D. & Mohr, I. Coupling 40S ribosome recruitment to modification of a cap-binding initiation factor by eIF3 subunit e. Genes Dev. 28, 835–840 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Wendel, H. G. et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 21, 3232–3237 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Furic, L. et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc. Natl Acad. Sci. USA 107, 14134–14139 (2010). This paper shows that eIF4E phosphorylation has a major role in prostate cancerogenesis and tumour progression and that targeting eIF4E phosphorylation is a promising target.
  Article CAS PubMed PubMed Central Google Scholar
• Joshi, S. & Platanias, L. C. MNK kinases in cytokine signaling and regulation of cytokine responses. Biomol. Concepts 3, 127–139 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Rosenwald, I. B. et al. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2α in response to growth induction by c-myc. Proc. Natl Acad. Sci. USA 90, 6175–6178 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Khanna-Gupta, A. et al. Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia. J. Biol. Chem. 287, 32728–32737 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Hariri, F. et al. The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia. Leukemia 27, 2047–2055 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Yi, T. et al. Hypoxia-inducible factor-1α (HIF-1α) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions. J. Biol. Chem. 288, 18732–18742 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Topisirovic, I. et al. Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer. Mol. Cell. Biol. 29, 1152–1162 (2009).
  Article CAS PubMed Google Scholar
• Jones, R. M. et al. An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol. Cell. Biol. 16, 4754–4764 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Lin, C. J. et al. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res. 68, 5326–5334 (2008).
  Article CAS PubMed Google Scholar
• van Riggelen, J., Yetil, A. & Felsher, D. W. MYC as a regulator of ribosome biogenesis and protein synthesis. Nature Rev. Cancer 10, 301–309 (2010).
  Article CAS Google Scholar
• Lazaris-Karatzas, A., Montine, K. S. & Sonenberg, N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA5′ cap. Nature 345, 544–547 (1990). This is the first description of a translation initiation factor (eIF4E ) with oncogenic properties. These findings spearheaded research into the role of translation initiation factors in cancer.
  Article CAS PubMed Google Scholar
• Rinker-Schaeffer, C. W. et al. Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of _ras_-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int. J. Cancer 55, 841–847 (1993).
  Article CAS PubMed Google Scholar
• De Benedetti, A. et al. Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F. Mol. Cell. Biol. 11, 5435–5445 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Wendel, H. G. et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332–337 (2004).
  Article CAS PubMed Google Scholar
• Ruggero, D. et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nature Med. 10, 484–486 (2004). This study establishes that eIF4E has oncogenic properties in vivo.
  Article CAS PubMed Google Scholar
• Mamane, Y. et al. eIF4E—from translation to transformation. Oncogene 23, 3172–3179 (2004).
  Article CAS PubMed Google Scholar
• Haydon, M. S. et al. Progression of eIF4e gene amplification and overexpression in benign and malignant tumors of the head and neck. Cancer 88, 2803–2810 (2000).
  Article CAS PubMed Google Scholar
• Raught, B. & Gingras, A. C. eIF4E activity is regulated at multiple levels. Int. J. Biochem. Cell Biol. 31, 43–57 (1999).
  Article CAS PubMed Google Scholar
• Hsieh, A. C. et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17, 249–261 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Avdulov, S. et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5, 553–563 (2004).
  Article CAS PubMed Google Scholar
• Lynch, M. et al. Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth. J. Biol. Chem. 279, 3327–3339 (2004).
  Article CAS PubMed Google Scholar
• Dowling, R. J. et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328, 1172–1176 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Petroulakis, E. et al. p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell 16, 439–446 (2009).
  Article CAS PubMed Google Scholar
• Martineau, Y. et al. Anti-oncogenic potential of the eIF4E-binding proteins. Oncogene 32, 671–677 (2013).
  Article CAS PubMed Google Scholar
• Zoncu, R., Efeyan, A. & Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature Rev. Mol. Cell Biol. 12, 21–35 (2011).
  Article CAS Google Scholar
• Topisirovic, I., Ruiz-Gutierrez, M. & Borden, K. L. Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res. 64, 8639–8642 (2004).
  Article CAS PubMed Google Scholar
• Robichaud, N. et al. Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene http://dx.doi.org/10.1038/onc.2014.146 (2014).
• Rosenwald, I. B. et al. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 18, 2507–2517 (1999).
  Article CAS PubMed Google Scholar
• Nathan, C. O. et al. Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 15, 1087–1094 (1997).
  Article CAS PubMed Google Scholar
• Chen, C. N. et al. Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome. J. Surg. Oncol. 86, 22–27 (2004).
  Article CAS PubMed Google Scholar
• Nathan, C. O. et al. Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J. Clin. Oncol. 17, 2909–2914 (1999). This is the first description of eIF4E expression levels as a prognostic biomarker in human cancer.
  Article CAS PubMed Google Scholar
• Guertin, D. A. & Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell 12, 9–22 (2007).
  Article CAS PubMed Google Scholar
• Sebolt-Leopold, J. S. & Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Rev. Cancer 4, 937–947 (2004).
  Article CAS Google Scholar
• Armengol, G. et al. 4E-binding protein 1: a key molecular “funnel factor” in human cancer with clinical implications. Cancer Res. 67, 7551–7555 (2007).
  Article CAS PubMed Google Scholar
• Graff, J. R. et al. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res. 69, 3866–3873 (2009).
  Article CAS PubMed Google Scholar
• Comtesse, N. et al. Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located on amplicon 3q26–27 in squamous cell carcinoma of the lung. Int. J. Cancer 120, 2538–2544 (2007).
  Article CAS PubMed Google Scholar
• Silvera, D. et al. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nature Cell Biol. 11, 903–908 (2009).
  Article CAS PubMed Google Scholar
• Liang, S. et al. Decreased expression of EIF4A1 after preoperative brachytherapy predicts better tumor-specific survival in cervical cancer. Int. J. Gynecol. Cancer 24, 908–915 (2014).
  Article PubMed Google Scholar
• Tu, L. et al. Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Mol. Cancer 9, 78 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Meric-Bernstam, F. et al. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res. 14, R138 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, Y. et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J. Pathol. 200, 640–646 (2003).
  Article CAS PubMed Google Scholar
• Mudduluru, G. et al. Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer 110, 1697–1707 (2007).
  Article CAS PubMed Google Scholar
• Wang, X. et al. Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma. Anticancer Res. 28, 2991–2996 (2008).
  CAS PubMed Google Scholar
• Gao, F. et al. PDCD4 gene silencing in gliomas is associated with 5′CpG island methylation and unfavourable prognosis. J. Cell Mol. Med. 13, 4257–4267 (2009).
  Article CAS PubMed Google Scholar
• Li, X. et al. Down-regulation of PDCD4 expression is an independent predictor of poor prognosis in human renal cell carcinoma patients. J. Cancer Res. Clin. Oncol. 138, 529–535 (2012).
  Article CAS PubMed Google Scholar
• Ramon, Y. C. S. et al. The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets. Clin. Transl. Oncol. 16, 937–941 (2014).
  Article CAS Google Scholar
• Wolff, A. C. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118–145 (2007).
  Article CAS PubMed Google Scholar
• Alain, T. et al. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res. 72, 6468–6476 (2012).
  Article CAS PubMed Google Scholar
• Mallya, S. et al. Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1. PLoS ONE 9, e88865 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Boussemart, L. et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature 513, 105–109 (2014).
  Article CAS PubMed Google Scholar
• Fruman, D. A. & Rommel, C. PI3K and cancer: lessons, challenges and opportunities. Nature Rev. Drug Discov. 13, 140–156 (2014).
  Article CAS Google Scholar
• Malina, A., Mills, J. R. & Pelletier, J. Emerging therapeutics targeting mRNA translation. Cold Spring Harb. Perspect. Biol. 4, a012377 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Vezina, C., Kudelski, A. & Sehgal, S. N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 28, 721–726 (1975).
  Article CAS Google Scholar
• Heitman, J., Movva, N. R. & Hall, M. N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253, 905–909 (1991). This study charts the discovery of TOR kinase.
  Article CAS PubMed Google Scholar
• Brown, E. J. et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369, 756–758 (1994).
  Article CAS PubMed Google Scholar
• Hara, K. et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177–189 (2002).
  Article CAS PubMed Google Scholar
• Kim, D. H. et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163–175 (2002).
  Article CAS PubMed Google Scholar
• Yang, H. et al. mTOR kinase structure, mechanism and regulation. Nature 497, 217–223 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Oshiro, N. et al. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 9, 359–366 (2004).
  Article CAS PubMed Google Scholar
• Sarbassov, D. D. et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296–1302 (2004).
  Article CAS PubMed Google Scholar
• Yip, C. K. et al. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol. Cell 38, 768–774 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Kang, S. A. et al. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 341, 1236566 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Yoon, S. O. & Roux, P. P. Rapamycin resistance: mTORC1 substrates hold some of the answers. Curr. Biol. 23, R880–R883 (2013).
  Article CAS PubMed Google Scholar
• Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159–168 (2006).
  Article CAS PubMed Google Scholar
• Lamming, D. W. et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335, 1638–1643 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Janes, M. R. & Fruman, D. A. Targeting TOR dependence in cancer. Oncotarget 1, 69–76 (2010).
  Article PubMed PubMed Central Google Scholar
• Benjamin, D. et al. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nature Rev. Drug Discov. 10, 868–880 (2011).
  Article CAS Google Scholar
• Harrington, L. S., Findlay, G. M. & Lamb, R. F. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem. Sci. 30, 35–42 (2005).
  Article CAS PubMed Google Scholar
• Choo, A. Y. & Blenis, J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 8, 567–572 (2009).
  Article CAS PubMed Google Scholar
• Yu, Y. et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322–1326 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065–3074 (2008).
  CAS PubMed PubMed Central Google Scholar
• Fan, Q. W. et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341–349 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Thoreen, C. C. et al.An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023–8032 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Feldman, M. E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009). References 159 and 160 are the first two studies describing the new generation of active-site mTOR inhibitors.
  Article CAS PubMed Google Scholar
• Garcia-Martinez, J. M. et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 421, 29–42 (2009).
  Article CAS PubMed Google Scholar
• Hresko, R. C. & Mueckler, M. mTOR·RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280, 40406–40416 (2005).
  Article CAS PubMed Google Scholar
• Sarbassov, D. D. et al. Phosphorylation and regulation of Akt/PKB by the rictor–mTOR complex. Science 307, 1098–1101 (2005).
  Article CAS PubMed Google Scholar
• Choo, A. Y. et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl Acad. Sci. USA 105, 17414–17419 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Chresta, C. M. et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70, 288–298 (2010).
  Article CAS PubMed Google Scholar
• Janes, M. R. et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Med. 16, 205–213 (2010).
  Article CAS PubMed Google Scholar
• Janes, M. R. et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia 27, 586–594 (2013).
  Article CAS PubMed Google Scholar
• Satheesha, S. et al. Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer. Mol. Cancer 10, 19 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ilic, N. et al. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc. Natl Acad. Sci. USA 108, E699–E708 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Cope, C. L. et al. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. J. Cell Sci. 127, 788–800 (2014).
  Article CAS PubMed Google Scholar
• Martineau, Y. et al. Pancreatic tumours escape from translational control through 4E-BP1 loss. Oncogene 33, 1367–1374 (2014).
  Article CAS PubMed Google Scholar
• Alain, T., Sonenberg, N. & Topisirovic, I. mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio. Oncotarget 3, 1491–1492 (2012).
  Article PubMed PubMed Central Google Scholar
• Coleman, L. J. et al. Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br. J. Cancer 100, 1393–1399 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Muranen, T. et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21, 227–239 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Larsson, S. C., Orsini, N. & Wolk, A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J. Natl Cancer Inst. 97, 1679–1687 (2005).
  Article PubMed Google Scholar
• Larsson, S. C., Mantzoros, C. S. & Wolk, A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int. J. Cancer 121, 856–862 (2007).
  Article CAS PubMed Google Scholar
• Pollak, M. Potential applications for biguanides in oncology. J. Clin. Invest. 123, 3693–3700 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Pollak, M. N. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2, 778–790 (2012).
  Article CAS PubMed Google Scholar
• Dowling, R. J. et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67, 10804–10812 (2007).
  Article CAS PubMed Google Scholar
• Konicek, B. W. et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res. 71, 1849–1857 (2011). This study shows that the orally available MNK inhibitor cercosporamide has anti-neoplastic properties.
  Article CAS PubMed Google Scholar
• Tschopp, C. et al. Phosphorylation of eIF-4E on Ser. 209 in response to mitogenic and inflammatory stimuli is faithfully detected by specific antibodies. Mol. Cell Biol. Res. Commun. 3, 205–211 (2000).
  Article CAS PubMed Google Scholar
• Knauf, U., Tschopp, C. & Gram, H. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol. Cell. Biol. 21, 5500–5511 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297–315 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Diab, S. et al. MAP kinase-interacting kinases-emerging targets against cancer. Chem. Biol. 21, 441–452 (2014).
  Article CAS PubMed Google Scholar
• Diab, S. et al. Discovery of 5-(2-(Phenylamino)pyrimidin-4-yl)thiazol-2(3_H_)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation. ChemMedChem 9, 962–972 (2014).
  Article CAS PubMed Google Scholar
• Xu, J. et al. Rational design of resorcylic acid lactone analogues as covalent MNK1/2 kinase inhibitors by tuning the reactivity of an enamide Michael acceptor. ChemMedChem 8, 1483–1494 (2013).
  Article CAS PubMed Google Scholar
• Ramalingam, S. et al. First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines. Oncotarget 5, 530–543 (2014).
  Article PubMed PubMed Central Google Scholar
• Adesso, L. et al. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway. Oncogene 32, 2848–2857 (2013).
  Article CAS PubMed Google Scholar
• Astanehe, A. et al. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition. Oncogene 31, 4434–4446 (2012).
  Article CAS PubMed Google Scholar
• Sun, S. Y. et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65, 7052–7058 (2005).
  Article CAS PubMed Google Scholar
• Sale, M. J. & S. J. Cook, Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer. Biochem. Soc. Trans. 42, 776–783 (2014).
  Article CAS PubMed Google Scholar
• DeFatta, R. J., Nathan, C. O. & De Benedetti, A. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope 110, 928–933 (2000).
  Article CAS PubMed Google Scholar
• Graff, J. R. et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J. Clin. Invest. 117, 2638–2648 (2007). This is a proof-of-principle study showing the anti-neoplastic effects of eIF4E ASO in vivo.
  Article CAS PubMed PubMed Central Google Scholar
• Lin, C. J. et al. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep. 1, 325–333 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Wagner, C. R., Iyer, V. V. & McIntee, E. J. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. Med. Res. Rev. 20, 417–451 (2000).
  Article CAS PubMed Google Scholar
• Ghosh, B. et al. Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem. Biol. 4, 367–377 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Li, S. et al. Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation. Mol. Pharm. 10, 523–531 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Jia, Y. et al. Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target. Med. Res. Rev. 32, 786–814 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, X. et al. Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA–cap interaction. J. Med. Chem. 55, 3837–3851 (2012).
  Article CAS PubMed Google Scholar
• Zochowska, M. et al. Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma. Nanomedicine 11, 67–76 (2014).
  Article CAS PubMed Google Scholar
• Kentsis, A. et al. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc. Natl Acad. Sci. USA 101, 18105–18110 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Yan, Y. et al. Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. RNA 11, 1238–1244 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Westman, B. et al. The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro. RNA 11, 1505–1513 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Assouline, S. et al. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 114, 257–260 (2009).
  Article CAS PubMed Google Scholar
• Malina, A. Cencic, R. & Pelletier, J. Targeting translation dependence in cancer. Oncotarget 2, 76–88 (2011).
  Article PubMed PubMed Central Google Scholar
• Marcotrigiano, J. et al. Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G. Mol. Cell 3, 707–716 (1999).
  Article CAS PubMed Google Scholar
• Matsuo, H. et al. Structure of translation factor eIF4E bound to m7GDP and interaction with 4E-binding protein. Nature Struct. Biol. 4, 717–724 (1997).
  Article CAS PubMed Google Scholar
• Fletcher, C. M. and Wagner, G., The interaction of eIF4E with 4E-BP1 is an induced fit to a completely disordered protein. Protein Sci. 7, 1639–1642 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Yanagiya, A. et al. Requirement of RNA binding of mammalian eukaryotic translation initiation factor 4GI (eIF4GI) for efficient interaction of eIF4E with the mRNA cap. Mol. Cell. Biol. 29, 1661–1669 (2009).
  Article CAS PubMed Google Scholar
• O'Leary, S. E. et al. Dynamic recognition of the mRNA cap by Saccharomyces cerevisiae eIF4E. Structure 21, 2197–2207 (2013).
  Article CAS PubMed Google Scholar
• Mader, S. et al. The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4γ and the translational repressors 4E-binding proteins. Mol. Cell. Biol. 15, 4990–4997 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Altmann, M. et al. A novel inhibitor of cap-dependent translation initiation in yeast: p20 competes with eIF4G for binding to eIF4E. EMBO J. 16, 1114–1121 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Moerke, N. J. et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128, 257–267 (2007).
  Article CAS PubMed Google Scholar
• Cencic, R. et al. Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication. J. Virol. 85, 6381–6389 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, L. et al. Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget 3, 869–881 (2012).
  PubMed PubMed Central Google Scholar
• Papadopoulos, E. et al. Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G. Proc. Natl Acad. Sci. USA 111, E3187–E3195 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Redondo, N. et al. Translation of viral mRNAs that do not require eIF4E is blocked by the inhibitor 4EGI-1. Virology 444, 171–180 (2013).
  Article CAS PubMed Google Scholar
• Willimott, S. et al. Cap-translation inhibitor, 4EGI-1, restores sensitivity to ABT-737 apoptosis through cap-dependent and -independent mechanisms in chronic lymphocytic leukemia. Clin. Cancer Res. 19, 3212–3223 (2013).
  Article CAS PubMed Google Scholar
• Ko, S. Y. et al. Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E. Clin. Cancer Res. 15, 4336–4347 (2009).
  Article CAS PubMed Google Scholar
• Bordeleau, M. E. et al. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nature Chem. Biol. 2, 213–220 (2006).
  Article CAS Google Scholar
• Bordeleau, M. E. et al. Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc. Natl Acad. Sci. USA 102, 10460–10465 (2005). This paper reports the discovery of pateamine, the first small-molecule targeting eIF4A.
  Article CAS PubMed PubMed Central Google Scholar
• Bordeleau, M. E. et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J. Clin. Invest. 118, 2651–2660 (2008).
  CAS PubMed PubMed Central Google Scholar
• Low, W. K. et al. Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol. Cell 20, 709–722 (2005).
  Article CAS PubMed Google Scholar
• Low, W. K. et al. Second-generation derivatives of the eukaryotic translation initiation inhibitor pateamine A targeting eIF4A as potential anticancer agents. Bioorg. Med. Chem. 22, 116–125 (2014).
  Article CAS PubMed Google Scholar
• Kuznetsov, G. et al. Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Mol. Cancer Ther. 8, 1250–1260 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Tsumuraya, T. et al. Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem. Pharmacol. 81, 713–722 (2011).
  Article CAS PubMed Google Scholar
• Cencic, R. et al. Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A. Blood Cancer J. 3, e128 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Cencic, R. et al. Antitumor activity and mechanism of action of the cyclopenta[_b_]benzofuran, silvestrol. PLoS ONE 4, e5223 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Sadlish, H. et al. Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex. ACS Chem. Biol. 8, 1519–1527 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, T. et al. Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors. J. Med. Chem. 55, 8859–8878 (2012).
  Article CAS PubMed Google Scholar
• Rubio, C. A. et al. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation. Genome Biol. 15, 476 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Zindy, P. et al. Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. Cancer Res. 71, 4068–4073 (2011).
  Article CAS PubMed Google Scholar
• Gupta, S. V. et al. Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. AAPS J. 13, 357–364 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Hawkins, B. C. et al. Simplified silvestrol analogues with potent cytotoxic activity. ChemMedChem 9, 1556–1566 (2014).
  Article CAS PubMed Google Scholar
• Hinnebusch, A. G. The scanning mechanism of eukaryotic translation initiation. Annu. Rev. Biochem. 83, 779–812 (2014).
  Article CAS PubMed Google Scholar
• Konieczny, A. & Safer, B. Purification of the eukaryotic initiation factor 2-eukaryotic initiation factor 2B complex and characterization of its guanine nucleotide exchange activity during protein synthesis initiation. J. Biol. Chem. 258, 3402–3408 (1983).
  CAS PubMed Google Scholar
• Krishnamoorthy, T. et al. Tight binding of the phosphorylated α subunit of initiation factor 2 (eIF2α) to the regulatory subunits of guanine nucleotide exchange factor eIF2B is required for inhibition of translation initiation. Mol. Cell. Biol. 21, 5018–5030 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Clemens, M. J. et al. Phosphorylation inhibits guanine nucleotide exchange on eukaryotic initiation factor 2. Nature 296, 93–95 (1982).
  Article CAS PubMed Google Scholar
• Ron, D. & Harding, H. in Translational Control in Biology and Medicine Ch. 13 (eds Matthews, M. B. et al.) (Cold Spring Harbor Laboratory Press, 2007).
  Google Scholar
• Dever, T. E. et al. Phosphorylation of initiation factor 2α by protein kinase GCN2 mediates gene-specific translational control of GCN4 in yeast. Cell 68, 585–596 (1992).
  Article CAS PubMed Google Scholar
• Harding, H. P. et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol. Cell 6, 1099–1108 (2000).
  Article CAS PubMed Google Scholar
• Mueller, P. P. & Hinnebusch, A. G. Multiple upstream AUG codons mediate translational control of GCN4. Cell 45, 201–207 (1986).
  Article CAS PubMed Google Scholar
• Vattem, K. M. & Wek, R. C. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc. Natl Acad. Sci. USA 101, 11269–11274 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Hinnebusch, A. G. Gene-specific translational control of the yeast GCN4 gene by phosphorylation of eukaryotic initiation factor 2. Mol. Microbiol. 10, 215–223 (1993).
  Article CAS PubMed Google Scholar
• Koromilas, A. E. & Mounir, Z. Control of oncogenesis by eIF2α phosphorylation: implications in PTEN and PI3K–Akt signaling and tumor treatment. Future Oncol. 9, 1005–1015 (2013).
  Article CAS PubMed Google Scholar
• Bi, M. et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J. 24, 3470–3481 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Donze, O. et al. Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. EMBO J. 14, 3828–3834 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Donze, O. et al. The protein kinase PKR: a molecular clock that sequentially activates survival and death programs. EMBO J. 23, 564–571 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, T. et al. Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target. Nature Chem. Biol. 7, 610–616 (2011).
  Article CAS Google Scholar
• Denoyelle, S. et al. In vitro inhibition of translation initiation by N,_N_-diarylureas — potential anti-cancer agents. Bioorg. Med. Chem. Lett. 22, 402–409 (2012).
  Article CAS PubMed Google Scholar
• Boyce, M. et al. A selective inhibitor of eIF2α dephosphorylation protects cells from ER stress. Science 307, 935–939 (2005).
  Article CAS PubMed Google Scholar
• Schewe, D. M. & Aguirre-Ghiso, J. A. Inhibition of eIF2α dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res. 69, 1545–1552 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Moenner, M. et al. Integrated endoplasmic reticulum stress responses in cancer. Cancer Res. 67, 10631–10634 (2007).
  Article CAS PubMed Google Scholar
• Hetz, C., Chevet, E. & Harding, H. P. Targeting the unfolded protein response in disease. Nature Rev. Drug Discov. 12, 703–719 (2013).
  Article CAS Google Scholar
• Tsaytler, P. et al. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science 332, 91–94 (2011).
  Article CAS PubMed Google Scholar
• Hamamura, K. et al. Attenuation of malignant phenotypes of breast cancer cells through eIF2α-mediated downregulation of Rac1 signaling. Int. J. Oncol. 44, 1980–1988 (2014).
  Article CAS PubMed Google Scholar
• Robert, F. et al. Initiation of protein synthesis by hepatitis C virus is refractory to reduced eIF2·GTP·Met-tRNAiMet ternary complex availability. Mol. Biol. Cell 17, 4632–4644 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Ollenschlager, G. et al. Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur. J. Clin. Invest. 18, 512–516 (1988).
  Article CAS PubMed Google Scholar
• Hill, J. M. et al. L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA 202, 882–888 (1967).
  Article CAS PubMed Google Scholar
• Buaboonnam, J. et al. Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. Pediatr. Blood Cancer 60, 1161–1164 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Bunpo, P. et al. GCN2 protein kinase is required to activate amino acid deprivation responses in mice treated with the anti-cancer agent L-asparaginase. J. Biol. Chem. 284, 32742–32749 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Tscherne, J. S. & Pestka, S. Inhibition of protein synthesis in intact HeLa cells. Antimicrob. Agents Chemother. 8, 479–487 (1975).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, M. T. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol. Pharmacol. 11, 511–519 (1975).
  CAS PubMed Google Scholar
• O'Brien, S. et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86, 3322–3326 (1995).
  CAS PubMed Google Scholar
• White, R. J. RNA polymerases I and III, growth control and cancer. Nature Rev. Mol. Cell Biol. 6, 69–78 (2005).
  Article CAS Google Scholar
• Drygin, D. et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 71, 1418–1430 (2011).
  Article CAS PubMed Google Scholar
• Bywater, M. J. et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 22, 51–65 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Jasiulionis, M. G. et al. Inhibition of eukaryotic translation initiation factor 5A (eIF5A) hypusination impairs melanoma growth. Cell Biochem. Funct. 25, 109–114 (2007).
  Article CAS PubMed Google Scholar
• Park, M. H. et al. Functional significance of eIF5A and its hypusine modification in eukaryotes. Amino Acids 38, 491–500 (2010).
  Article CAS PubMed Google Scholar
• Cook, D. et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nature Rev. Drug Discov. 13, 419–431 (2014).
  Article CAS Google Scholar
• Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).
  Article CAS PubMed Google Scholar
• Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520–529 (2012).
  Article CAS PubMed Google Scholar
• Yardley, D. A. et al. Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv. Ther. 30, 870–884 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Hess, G. et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 27, 3822–3829 (2009).
  Article CAS PubMed Google Scholar
• Figlin, R. A. Mechanisms of disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. Nature Clin. Pract. Oncol. 5, 601–609 (2008).
  Article CAS Google Scholar
• Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Krueger, D. A. et al. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology 80, 574–580 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Demetri, G. D. et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J. Clin. Oncol. 31, 2485–2492 (2013).
  Article CAS PubMed Google Scholar
• Buzzai, M. et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67, 6745–6752 (2007).
  Article CAS PubMed Google Scholar
• Memmott, R. M. et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev. Res. (Phila) 3, 1066–1076 (2010).
  Article CAS Google Scholar
• Algire, C. et al. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr. Relat. Cancer 15, 833–839 (2008).
  Article CAS PubMed Google Scholar
• Schneider, M. B. et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120, 1263–1270 (2001).
  Article CAS PubMed Google Scholar
• Hong, D. S. et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin. Cancer Res. 17, 6582–6591 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Lin, C. J., Malina, A. & Pelletier, J. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy. Cancer Res. 69, 7491–7494 (2009).
  Article CAS PubMed Google Scholar
• White, R. J. RNA polymerases I and III, non-coding RNAs and cancer. Trends Genet. 24, 622–629 (2008).
  Article CAS PubMed Google Scholar
• Raynaud, F. I. et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67, 5840–5850 (2007).
  Article CAS PubMed Google Scholar
• Suissa, S. & Azoulay, L. Metformin and cancer: mounting evidence against an association. Diabetes Care 37, 1786–1788 (2014).
  Article CAS PubMed Google Scholar
• Park, M. H., Wolff, E. C., Lee, Y. B. & Folk, J. E. Antiproliferative effects of inhibitors of deoxyhypusine synthase. Inhibition of growth of Chinese hamster ovary cells by guanyl diamines. J. Biol. Chem. 269, 27827–27832 (1994).
  CAS PubMed Google Scholar